Singapore, July 30 -- Viridian Therapeutics, Inc., a US-based biopharmaceutical company focused on discovering, developing, and commercialising potential best-in-class medicines for serious and rare diseases, has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co. to develop and commercialise veligrotug and VRDN-003 in Japan.

Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies for the potential treatment of patients with thyroid eye disease (TED), and VRDN-003 is a potential best-in-class, subcutaneous, half-life extended anti-IGF-1R antibody with the same binding domain as veligrotug. TED is an autoimmune condition characterised by inflammation, growth, and damage to...